Beijing Kidney Medical Technology Co., Ltd.

Beijing Kidney Medical Technology Co. , Ltd. specializes in innovative digital solutions for kidney disease management, providing education and support to patients through an interactive platform that connects them with professional healthcare providers. Founded in 2015 in Beijing, China, Beijing Kidney Medical Technology Co.

, Ltd. focuses on kidney disease management and education. The company successfully raised CNY 100 million in Series A funding on October 12, 2021, from investors including Heyu Capital and Shunwei Capital Partners. The founder has a background in medical technology innovation.

肾上线 (Shenshanxian) operates as a comprehensive digital platform focused on kidney disease education and management. Its core offerings are centered around an interactive community for kidney disease patients, providing valuable resources and support tailored to their needs. This includes professional guidance from nephrologists, educational materials on kidney health, and interactive forums for patients to engage with one another and medical professionals. The platform aims to empower users with knowledge, enabling them to manage their conditions effectively and improve their overall quality of life.

The end users primarily include patients diagnosed with kidney diseases in China, with plans to expand access to global markets, targeting regions with a significant prevalence of kidney-related health issues. The company generates revenue through a mix of subscription services and partnerships with healthcare providers. Clients, including individuals and healthcare institutions, engage with the platform through various subscription plans that provide access to exclusive educational content, personalized management solutions, and community support. The transactions structure is direct-to-consumer, allowing individuals to pay for membership or specific services, while institutional partnerships may involve bulk subscription agreements for healthcare facilities.

Through this framework, 肾上线 is positioned to generate revenue while enhancing patient engagement and education in kidney health management. Following the CNY 100 million raised in Series A funding in October 2021, Beijing Kidney Medical Technology Co. , Ltd. aims to accelerate clinical research for digital medical treatments for chronic diseases and expand its follow-up team.

The company is designing new products to enhance patient interactions and plans to enter new geographic markets, including areas with high kidney disease prevalence, by the end of 2023.